scholarly journals Neutralizing antibody responses to SARS-CoV-2: a population based seroepidemiological analysis in Delhi, India

2021 ◽  
Author(s):  
Pragya Sharma ◽  
Ekta Gupta ◽  
Saurav Basu ◽  
Reshu Aggarwal ◽  
Suruchi Mishra ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
State Level ◽  
Neutralizing Antibody ◽  
Simple Random Sampling ◽  
Population Based ◽  
Strongly Correlated ◽  
Community Based ◽  
Cross Sectional ◽  
Neutralizing Capacity ◽  
Sectional Analysis

We conducted this study to estimate seroprevalence of neutralizing antibodies in the general population and to further correlate it with the IgG SARS-CoV-2 IgG levels. This present cross-sectional analysis was conducted as a sequel to a state level community-based seroepidemiological study in Delhi, India. A total of 2564 seropositive samples were selected from 25622 seropositive samples through simple random sampling. Neutralizing capacity was estimated by performing a surrogate virus neutralization test with the sVNT (GenScript) assay. Neutralizing antibody against the SARS-CoV-2 virus was operationally considered as detected when the signal inhibition was ≥30%. A total of 2233 (87.1%, 95% C.I. 85.7, 88.3) of the 2564 SARS-CoV-2 seropositive samples had detectable neutralizing antibodies. On bi-variate analysis but not on adjusted analysis, Covid-19 vaccination showed a statistically significant association with the presence of neutralizing antibodies (p<0.001). The signal/ cut off (S/CO) of SARS-CoV-2 IgG ranged from 1.00 to 22.8 (median 11.40). In samples with S/CO ≥4.00, the neutralizing antibodies ranged from 94.5 to 100%, while in samples with S/CO <4.00, it ranged from 52.0 to 79.2%. The neutralizing antibody seroprevalence strongly correlated with the S/CO range (r=0.62, p=0.002). In conclusion, in populations with high SARS-CoV-2 seroprevalence, neutralizing antibodies are generated in nearly 9 of 10 seropositive individuals.

scholarly journals Persistence of Neutralizing Antibody Responses Among Yellow Fever Virus 17D Vaccinees Living in a Nonendemic Setting

2019 ◽  
Vol 221 (12) ◽  
pp. 2018-2025 ◽  
Author(s):  
Bettie W Kareko ◽  
Brian L Booty ◽  
Chad D Nix ◽  
Zoe L Lyski ◽  
Mark K Slifka ◽  
...  
Keyword(s):  
Logistic Regression ◽  
Yellow Fever ◽  
Neutralizing Antibodies ◽  
Yellow Fever Virus ◽  
Booster Vaccination ◽  
Neutralizing Antibody ◽  
Fever Virus ◽  
Cross Sectional ◽  
Vaccination History ◽  
Sectional Analysis

Abstract Background The once-in-a-lifetime recommendation for vaccination against yellow fever virus (YFV) has been controversial, leading to increased scrutiny of the durability of immunity after 17D vaccination. Methods This is a cross-sectional analysis of 17D vaccinees living in nonendemic Portland, Oregon. Neutralization assays were used to determine YFV immunity. The relationships between 17D immunity and vaccination history, demographics, and travel were evaluated using nominal logistic regression. Results Seventy-one of 92 (77.2%) subjects were YFV seropositive (90 percent plaque reduction neutralization test ≥1:10) at all timepoints, and 24 of 38 (63.8%) were YFV seropositive at ≥10 years after single-dose vaccination. No relationship was found between YFV immunity and time in endemic countries, other flavivirus immunity, or demographics. Subjects were most likely to become seronegative between 3 and 12 years postvaccination (logistic regression, odds ratio [OR] = 1.75; 95% confidence interval [CI], 1.12–2.73). A comparison of our results and 4 previous studies of YFV nonendemic vaccinees found that overall, 79% (95% CI, 70%–86%) of vaccinees are likely to be seropositive ≥10 years postvaccination. Conclusions These results suggest that 1 in 5 17D vaccinees will lack neutralizing antibodies at ~10 years postvaccination, and a booster vaccination should be considered for nonendemic vaccinees before travel to regions where there is a high risk of YFV transmission.

scholarly journals The association between serum alanine aminotransferase and hypertension: A national based cross-sectional analysis among over 21 million Chinese adults

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Jiajing Jia ◽  
Ying Yang ◽  
Fangchao Liu ◽  
Minjin Zhang ◽  
Qin Xu ◽  
...  
Keyword(s):  
Alanine Aminotransferase ◽  
Elevated Serum ◽  
Population Based ◽  
Reproductive Age ◽  
Chinese Adults ◽  
Cross Sectional ◽  
Serum Alanine Aminotransferase ◽  
Cross Sectional Analysis ◽  
Registration Data ◽  
Sectional Analysis

Abstract Background Inconsistent results were found in the association between serum alanine aminotransferase (ALT) and hypertension among population-based studies. This study evaluated the association between ALT and hypertension among Chinese reproductive-age population by utilizing registration data from National Free Pre-pregnancy Checkups Project in 2016–2017. Methods The 21,103,790 registered participants were eligible for analysis, including women who were 20–49 years old and men who were 20–59 years old with available data for ALT and blood pressure (BP). Logistic regression was conducted to estimate odds ratio (OR) for the association between ALT and hypertension as a binary outcome. Linear regression was used to examine the association between ALT and BP as a continuous outcome. Results In total, 4.21% of the participants were hypertensive, and 11.67% had elevated ALT (> 40 U/L). Hypertension prevalence was 3.63% and 8.56% among participants with normal and elevated ALT levels. A strong linear relationship was found between serum ALT levels and the odds of hypertension after adjustment for potential confounders. The multivariable-adjusted ORs for hypertension were 1, 1.22 (1.21, 1.22), 1.67 (1.65 1.68), 1.78 (1.76, 1.80), and 1.92 (1.90, 1.94) in participants with ALT levels of ≤ 20, 20.01–40, 40.01–60, 60.01–80, and > 80 U/L, respectively. Systolic and diastolic BPs rose by 1.83 and 1.20 mmHg on average, for each 20 U/L increase in ALT (P for trend < 0.001). The association was consistent among subgroups and tended to be stronger among populations who are overweight (body mass index ≥ 24 kg/m2) (χ2 = 52,228, P < 0.001), alcohol drinking (χ2 = 100,730, P < 0.001) and cigarette smoking (χ2 = 105,347, P < 0.001). Conclusions Our cross-sectional analysis suggested a linear association between serum ALT and hypertension or BP, which indicated that abnormal liver metabolism marked by elevated serum ALT could play a role in hypertension or elevated BP condition.

scholarly journals Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
N. Ahmad Aziz ◽  
Victor M. Corman ◽  
Antje K. C. Echterhoff ◽  
Marcel A. Müller ◽  
Anja Richter ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Response Rate ◽  
Neutralization Test ◽  
Population Based ◽  
Immunofluorescence Assay ◽  
Test Results ◽  
Community Based ◽  
Population Based Study ◽  
Temporal Course ◽  
Confirmatory Tests

AbstractTo estimate the seroprevalence and temporal course of SARS-CoV-2 neutralizing antibodies, we embedded a multi-tiered seroprevalence survey within an ongoing community-based cohort study in Bonn, Germany. We first assessed anti-SARS-CoV-2 immunoglobulin G levels with an immunoassay, followed by confirmatory testing of borderline and positive test results with a recombinant spike-based immunofluorescence assay and a plaque reduction neutralization test (PRNT). Those with a borderline or positive immunoassay result were retested after 4 to 5 months. At baseline, 4771 persons participated (88% response rate). Between April 24th and June 30th, 2020, seroprevalence was 0.97% (95% CI: 0.72−1.30) by immunoassay and 0.36% (95% CI: 0.21−0.61) when considering only those with two additional positive confirmatory tests. Importantly, about 20% of PRNT+ individuals lost their neutralizing antibodies within five months. Here, we show that neutralizing antibodies are detectable in only one third of those with a positive immunoassay result, and wane relatively quickly.

Non-pharmacological management of adult asthma in Australia: cross-sectional analysis of a population-based cohort study

2018 ◽  
Vol 57 (1) ◽  
pp. 105-112 ◽  
Author(s):  
Daniel J. Tan ◽  
John A. Burgess ◽  
Jennifer L. Perret ◽  
Dinh S. Bui ◽  
Michael J. Abramson ◽  
...  
Keyword(s):  
Cohort Study ◽  
Population Based ◽  
Cross Sectional ◽  
Pharmacological Management ◽  
Adult Asthma ◽  
Cross Sectional Analysis ◽  
Sectional Analysis

scholarly journals Cross-sectional analysis of a community-based cooperative grocery store intervention in Saskatoon, Canada

2015 ◽  
Vol 106 (3) ◽  
pp. e147-e153 ◽  
Author(s):  
Larisa C. Lotoski ◽  
Rachel Engler-Stringer ◽  
Nazeem Muhajarine
Keyword(s):  
Grocery Store ◽  
Community Based ◽  
Cross Sectional ◽  
Cross Sectional Analysis ◽  
Sectional Analysis

scholarly journals Comorbidities in adults with asthma: Population-based cross-sectional analysis of 1.4 million adults in Scotland

2017 ◽  
Vol 47 (10) ◽  
pp. 1246-1252 ◽  
Author(s):  
C. J. Weatherburn ◽  
B. Guthrie ◽  
S. W. Mercer ◽  
D. R. Morales
Keyword(s):  
Population Based ◽  
Cross Sectional ◽  
Cross Sectional Analysis ◽  
Sectional Analysis

scholarly journals Prevalence of eczema among older persons: A population-based cross-sectional study

2021 ◽  
Vol 0 ◽  
pp. 1-5
Author(s):  
Vijayan Neena ◽  
Neelakandhan Asokan ◽  
Rajany Jose ◽  
A. Sarin
Keyword(s):  
Older Persons ◽  
Health Workers ◽  
Age Groups ◽  
Medical Knowledge ◽  
Population Based ◽  
Cross Sectional Survey ◽  
Community Based Interventions ◽  
Community Based ◽  
Cross Sectional ◽  
Lichen Simplex Chronicus

Background: There are very few population-based studies on the prevalence of eczema among older persons Aims: To estimate the prevalence and types of eczema in those aged 65 years or more in the community and to evaluate the effectiveness of community-based interventions for case finding. Methods: In the first stage of this cross-sectional survey, trained health workers of a non-governmental organization surveyed the eligible population and identified persons likely to have eczema. In the second stage, dermatologists examined such persons to ascertain the diagnosis. Statistical analysis was done using Epi Info software version 7. Prevalence of eczema was expressed in percentages. Chi-square test was used for comparing the difference in prevalence of eczema in various age groups and sex. Results: Health workers identified 98 persons as possible cases of eczema after interviewing 385 older persons in the community. Among them 95 persons were examined by dermatologists and 44 were confirmed to have eczema (diagnostic accuracy of health workers = 46.3%).Point prevalence of eczema was 11.4% (44/385). Prevalence was similar in males and females. It was greater (18.2 %) among persons aged 81 years or more. Asteatotic eczema, gravitational eczema and lichen simplex chronicus were the more common types of eczema. Limitations: Possible underestimation of the prevalence rates due to limited medical knowledge of health workers; limited facilities for examination and investigations at the medical camps and home visits. Conclusion: There appears to be a considerable burden of eczema among older persons in the community. A community-based approach involving non-governmental organizations has the potential to identify cases and offer care close to their homes.

scholarly journals Duration of immunity against COVID-19 after vaccination in Indian subcontinent

2022 ◽  
Author(s):  
Apoorva Munigela ◽  
Sasikala M ◽  
Gujjarlapudi Deepika ◽  
Anand V Kulkarni ◽  
Krishna Vemula ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Booster Dose ◽  
Indian Subcontinent ◽  
Neutralizing Antibody ◽  
Health Concern ◽  
Mortality Data ◽  
Optimal Timing ◽  
Cross Sectional ◽  
Mortality And Morbidity ◽  
Antibody Levels

Abstract Coronavirus disease (COVID-19) continues to be a major health concern leading to substantial mortality and morbidity across the world. Vaccination is effective in reducing the severity and associated mortality. Data pertaining to the duration of immunity, antibody waning and the optimal timing of booster dose administration is limited. In this cross-sectional study, we assessed the antibody levels in healthcare workers who were fully vaccinated after obtaining Institutional ethics committee approval and informed consent. Whole blood was collected and enumeration of S1/S2 neutralizing antibody levels was carried out using LIAISON SARS-COV-2 S1/S2 IgG assay. A total of 1636 individuals who were vaccinated with Covaxin or Covishield were included. Of these, 52% were males with a median age of 29 years. Diabetes and Hypertension was noted in 2.32% (38/1636) and 2.87% (47/1636) of the individuals. Spike neutralizing antibodies were below the detectable range (<15 AU/ml) in 6.0% (98/1636) of the individuals. Decline in neutralizing antibody was seen in 30% of the individuals above 40 years of age with comorbidities (diabetes and hypertension) after 6 months. These individuals may be prioritized for a booster dose at 6 months.

Sign in / Sign up

Export Citation Format

Share Document